CClinicalTrials.gg
CompletedNCT00253929Updated Apr 5, 2007

Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia

An interventional study of Intra-arterial infusion of adenosine and intra-arterial infusion of caffeine in Blood Flow in Healthy Volunteers, sponsored by Radboud University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-04-05.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The endogenous nucleoside adenosine can induce various cardiovascular and neurohumoral effects by stimulation of specific adenosine receptors. taken together these effects protect against ischaemia-reperfusion injury of (myocardial)muscles and agsinst the development of atherosclerosis. Genetic variations in genes encoding for adenosine receptors or for enzymes involved in the formation or breakdown of adenosine could potentially modulate these effects. In this study, we aim to determine the functional effects of two frequent genetic polymorphisms in the adenosine receptor and AMPdeaminase (involved in the formation of adenosine) on the vascular effects of adenosine.

Read the detailed description

The endogenous nucleoside adenosine can induce various cardiovascular and neurohumoral effects by stimulation of specific adenosine receptors. taken together these effects protect against ischaemia-reperfusion injury of (myocardial)muscles and agsinst the development of atherosclerosis. Genetic variations in genes encoding for adenosine receptors or for enzymes involved in the formation or breakdown of adenosine could potentially modulate these effects. In this study, we aim to determine the functional effects of two frequent genetic polymorphisms in the adenosine receptor and AMPdeaminase (involved in the formation of adenosine) on the vascular effects of adenosine.

In 100 healthy young volunteers, we will determine the genotype of the adenosine A2A receptor gene. We expect to find approximately 15 subjects with the 1976T>C polymorphisms. It is known that this polymorphism is associated with an increased neuropsychological sensitivity to caffeine administration.

We will explore whether this polymorphism is associated with a different vasodilating response to the administration of adenosine and caffeine into the brachial artery. Blood flow will be measured with venous occlucion plethysmography.

Secondly, we will also determine the genotype of the AMPD1 gene. We expect to find 15 subjects with the 34C>T mutation, which is a loss-of-function-mutation. Cardiovascular patients with this mutation are known to have a survival benefit. We will explore whether the post-occlusive reactive hyperemia in the forearm is potentiated, because during ischaemia, more adenosine is formed in these subjects.

02

Conditions studied

  • Blood Flow in Healthy Volunteers

Browse trials for

Keywords

  • adenosine
  • polymorphisms
  • blood flow
  • adenosine A2a receptor
  • AMP deaminase
03

In context

Hyperemia

85 studies on the registry are indexed under Hyperemia; 37 are open to participants now.

This study's enrollment of 100 is above the median of 60 across 43 interventional studies indexed under Hyperemia.

Browse Hyperemia studies →

Lead sponsor

Radboud University Medical Center is the lead sponsor of 959 studies on the registry; 134 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18-40 year

Exclusion criteria

Exclusion Criteria:

  • hypertension
  • diabetes
  • cardiovascular or pulmonary disease
  • asthma
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants

Interventions

  • DrugIntra-arterial infusion of adenosine
  • Drugintra-arterial infusion of caffeine
  • Drugintra-arterial infusion of acetylcholine
  • Drugintra-arterial infusion of sodium nitroprusside
  • ProcedureOcclusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes
06

What researchers measure

Primary outcomes

  1. A2A: adenosine- and caffeine induced vasomotion (blood flow)

  2. AMPD:post-occlusive reactibe hyperemic blood flow

07

Study locations

1 site
  • Radboud University Nijmegen Medical Centre
    Nijmegen, Gelderland 6500HB, Netherlands
08

References and documents

Publications

  • Riksen NP, Franke B, van den Broek P, Naber M, Smits P, Rongen GA. The 22G>A polymorphism in the adenosine deaminase gene impairs catalytic function but does not affect reactive hyperaemia in humans in vivo. Pharmacogenet Genomics. 2008 Oct;18(10):843-6. doi: 10.1097/FPC.0b013e328305e630. PubMed 18794722 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00253929
Lead sponsor
Radboud University Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Nov 15, 2005
Start date
Nov 2005
Completion
Feb 2006
Last update
Apr 5, 2007

Study contacts

Gerard Rongen, MD, PhD
principal investigator · Radboud University Medical Center
Paul Smits, MD, PhD
principal investigator · Radboud University Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion